Thoracic Epidural Analgesia Is Not Associated With Improved Survival After Pancreatic Surgery: Long-Term Follow-Up of the Randomized Controlled PAKMAN Trial
Primary result · Overall survivalResult — go to the resultHazard ratio 1.176 95% CI 0.809–1.710, event not clearly statedAuthors' conclusion
Results from this long-term follow-up of the PAKMAN randomized controlled trial do not support favoring EDA over PCIA in pancreatic surgery.
Study context
- Population
- Patients after partial pancreatoduodenectomy
- Participants
- 220 patients
- Comparison
- Thoracic epidural analgesia vs patient-controlled IV analgesia
- Epidural analgesia (EDA)n = 109
- Patient-controlled intravenous analgesia (PCIA)n = 111reference
- Primary endpoint
- Overall survival
- Follow-up
- 3 to 5 years after index surgery
Methodological detailslong-term follow-up, adaptive, pragmatic, international, multicentre, superiority
- Long-term follow-up
- Adaptive
- Pragmatic
- International
- Multicentre
- Superiority
Primary result
As reported in the abstract
Hazard ratio
1.176
95% CI 0.809–1.710, event not clearly stated
P = 0.397
EDA vs PCIA
HR 1.176 (95% CI 0.809–1.710), event not clearly stated; P = 0.397
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Overall survival, malignancies only (subgroup)n = 179 | 1.369 (0.932–2.011) | P = 0.109 | |
| 0.512Hazard ratio (log scale) |
Recurrence-free survival
- Recurrence-free survival did not differ between groups
Long-term quality of life (QoL) and pain severity
- Similar in both groups (EDA: n = 40, PCIA: n = 45)
- Questionnaire response rate: 94%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Thoracic Epidural Analgesia Is Not Associated With Improved Survival After Pancreatic Surgery: Long-Term Follow-Up of the Randomized Controlled PAKMAN Trial. Anesth Analg. Published 9 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →